No, metformin must be discontinued with an eGFR of 28 mL/min/1.73 m²
Metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² and must be stopped immediately. This is a clear, non-negotiable threshold established by both the 2022 KDIGO guidelines and FDA labeling 1, 2.
Why This Cutoff Exists
The primary concern is metformin-associated lactic acidosis, a rare but potentially fatal complication. At eGFR <30 mL/min/1.73 m², metformin accumulates because the kidney cannot adequately clear it (metformin is substantially excreted renally). This accumulation increases lactate levels and creates a dangerous metabolic environment 2.
Recent real-world evidence supports this threshold: a large cohort study of over 75,000 patients demonstrated that metformin use was associated with increased risk of acidosis specifically at eGFR <30 mL/min/1.73 m² (adjusted HR 2.07; 95% CI 1.33-3.22), while showing no increased risk at eGFR 30-44 mL/min/1.73 m² 3. This validates the current guideline cutoff.
The Clear Algorithm for eGFR-Based Metformin Management
According to KDIGO 2022 1:
- eGFR ≥60: Continue full dose, monitor annually
- eGFR 45-59: Continue same dose, but consider reduction if patient has conditions predisposing to hypoperfusion/hypoxemia; monitor every 3-6 months
- eGFR 30-44: Halve the dose; do not initiate if not already on metformin; monitor every 3-6 months
- eGFR <30: Stop metformin immediately; do not initiate
What to Do Instead at eGFR 28
With eGFR of 28 mL/min/1.73 m², you should:
- Discontinue metformin immediately
- Prioritize SGLT2 inhibitors if eGFR ≥20 mL/min/1.73 m² (particularly if albuminuria or heart failure present) - these have proven kidney and cardiovascular benefits even at this level of renal function 4
- Consider GLP-1 receptor agonists - most require no dose adjustment in CKD and provide cardiovascular benefits 1
- Use DPP-4 inhibitors, insulin, or other agents as needed for glycemic control
Critical Pitfalls to Avoid
Do not continue metformin "just a little longer" while transitioning therapy. The risk-benefit ratio clearly shifts against metformin below eGFR 30, with observational data showing increased mortality and acidosis risk in very elderly patients with advanced CKD 5.
Do not restart metformin if eGFR temporarily improves above 30 without ensuring stability - acute fluctuations in renal function are common in advanced CKD, and the patient may quickly drop back below the safety threshold.
Monitor eGFR frequently (every 3 months minimum) in patients approaching this threshold to catch the decline before reaching contraindicated levels 1.
Additional Monitoring Considerations
If the patient was on metformin long-term before discontinuation, check vitamin B12 levels as metformin causes malabsorption, particularly after >4 years of use 1, 6.
The evidence is unequivocal and consistent across guidelines, FDA labeling, and contemporary research: metformin must be stopped at eGFR 28 mL/min/1.73 m² 1, 2, 7, 8, 3.